OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO

A Boston biotech with a hefty backing from OrbiMed is making its Nasdaq debut Thursday.

Theseus Pharmaceuticals priced its IPO at $16 per share, the high end of its range, jumping to the public market roughly six months after OrbiMed led the biotech’s nine-figure Series B. Theseus netted $160 million for the public offering, bringing the sector’s total combined 2021 raise to $13.74 billion across 86 different companies, per the Endpoints News tally.